Importance of homocysteine, lipoprotein (a) and non-classical cardiovascular risk factors (fibrinogen and advanced glycation end-products) for atherogenesis in uraemic patients
Open Access
- 2 October 2000
- journal article
- review article
- Published by Oxford University Press (OUP) in Nephrology Dialysis Transplantation
- Vol. 15 (suppl_5) , 81-91
- https://doi.org/10.1093/ndt/15.suppl_5.81
Abstract
Ziad A. Massy; Importance of homocysteine, lipoprotein (a) and non‐classical cardiovascular risk factors (fibrinogen and advanced glycation end‐products) for aKeywords
This publication has 122 references indexed in Scilit:
- Inflammation enhances cardiovascular risk and mortality in hemodialysis patientsKidney International, 1999
- Oral or parenteral therapy for B12 deficiencyThe Lancet, 1998
- MTHFR association with arteriosclerotic vascular disease?Human Genetics, 1998
- Proportionate increase of fibrinogen and albumin synthesis in nephrotic patients: Measurements with stable isotopesKidney International, 1998
- Carotid artery lesions in patients with nondiabetic chronic renal failureAmerican Journal of Kidney Diseases, 1996
- High dose B-vitamin treatment of hyperhomocysteinemia in dialysis patientsKidney International, 1996
- Serum Lipoprotein (a) Concentration Is Increased in Moderate Renal FailureNephron, 1996
- N.epsilon.-(Carboxymethyl)lysine Is a Dominant Advanced Glycation End Product (AGE) Antigen in Tissue ProteinsBiochemistry, 1995
- No Association Between Plasma Lipoprotein(a) Concentrations and the Presence or Absence of Coronary Atherosclerosis in African-AmericansArteriosclerosis, Thrombosis, and Vascular Biology, 1995
- Hyperhomocysteinemia and traditional cardiovascular disease risk factors in end-stage renal disease patients on dialysis: a case-control studyAtherosclerosis, 1995